Problems of Radiation Medicine and Radiobiology

I. S. Dyagil, V. V. Sholoyko, Yu. O. Silayev, Z. V. Martina, I. V. Dmytrenko, A. O. Tovstogan,
V. G. Fedorenko, T. Yu. Shlyakhtychenko, Zh. M. Minchenko

State Institution «National Research Center for Radiation Medicine of the National Academy of Medical Sciences of Ukraine», 53 Melnykova str., Kyiv, 04050, Ukraine

CASE OF DEVELOPMENT OF NON/HODGKIN'S MALIGNANT LYMPHOMA ON THE BACKGROUND OF CHRONIC MYELOID LEUKEMIA IN A PATIENT WHO SUFFERED OF THE CHORNOBYL ACCIDENT

In this paper, a clinical case of combination of chronic myeloid leukemia and T-lymphoblastic lymphoma is presented, which is currently a rather rare finding for a clinician. The diagnosis of T-lymphoblastic lymphoma is established after 2 years from the verification of chronic myeloid leukemia. The course of diseases and approaches to treatment are described. The pathogenetic relationship between myeloid and lymphoid diseases remains unclear and is likely to be the result of several factors – radiation, chemical and, consequently, genetic disorders.
Key words: chronic myeloid leukemia, T-lymphoblastic lymphoma, Chornobyl catastrophe, small doses of ionizing radiation, chemical loading.

Problems of radiation medicine and radiobiology.
2018;23:517_523. doi: 10.33145/2304-8336-2018-23-517-523

full text

1. Baccarani M, Deininger MW, Rosti G, Hochhaus A, Soverini S, Apperley JF, et al. European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. Blood. 2013;122(6):872-84. doi: 10.1182/blood-2013-05-501569.

2. Miranda MB, Lauseker M, Kraus M-P, Proetel U, Hanfstein B, Fabarius A, et al. Secondary malignancies in CML patients - data from the German CML study IV. Blood. 2012;120(21):3746.

3. Miranda MB, Lauseker M, Kraus M-P, Proetel U, Hanfstein B, Fabarius A, et al. Secondary malignancies in chronic myeloid leukemia patients after imatinib-based treatment: long-term observation in CML Study IV. Leukemia. 2016;30(6):1255-62. doi: 10.1038/leu.2016.20.

4. Acar H, Ecirli S, Gundogan F, Bulay O, Acar A. Simultaneous occurrence of chronic myelogenous leukemia and non-Hodgkin lymphoma at diagnosis. Cancer Genet Cytogenet. 1999;108(2):171-4.

5. Kissova J, Ovesna P, Penka M, Bulicova A, Kiss I. Second malignancies in philadelphia-negative myeloproliferative neoplasms - single-center experience. Anticancer Res. 2014;34(5):2489-96.

6. Latagliata R, Spadea A, Cedrone M, Di Giandomenico J, De Muro M, Villiva N, et al. Symptomatic mucocutaneus toxicity of hydroxyurea in Philadelphia chromosome-negative myeloproliferative neoplasms: the Mister Hyde face of a safe drug. Cancer. 2012;118(2):404-9. doi: 10.1002/cncr.26194.

7. Finazzi G, Ruggeri M, Rodeghiero F, Barbui T. Second malignancies in patient with essential thrombocythemia treated with busulfan and hydroxyurea: long-term follow-up of a randomized clinical trial. Br J Haematol. 2000;110(3):577-83.

8. Sterkers Y, Preudhomme C, Lai JL, Demory JL, Caulier MT, Wattel E, et al. Acute myeloid leukemia and myelodysplastic syndromes following essential thrombocythemia treated with hydroxyurea: high proportion of cases with 17p deletion. Blood. 1998;91(2):616-22.

9. McEvoy GK, editor. AHFS 2006 Drug Information. Bethesda, Maryland: American Sosiety of Health-System Pharmacists, Inc;2006. p. 1067-72.

10. Kim MA, Lee GW, Maeng KY. An unusual presenting feature of precursor T-cell acute lymphoblastic leukemia/lymphoma. Ann. Hematol. 2005;84(8):553-4. DOI: 10.1007/s00277-005-1042-4.

11. Bartkowiak D, Humble N, Suhr P, Hagg J, Mair K, Polivka B, et al. Second cancer after radiotherapy, 1981-2007. Radiother Oncol. 2012;105(1):122-6. doi: 10.1016/j.radonc.2011.09.013.